Roquefort Therapeutics (LSE:ROQ) Change In Receivables : £0.10 Mil (TTM As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Change In Receivables?

Roquefort Therapeutics's change in receivables for the quarter that ended in Jun. 2024 was £0.07 Mil. It means Roquefort Therapeutics's Accounts Receivable declined by £0.07 Mil from Dec. 2023 to Jun. 2024 .

Roquefort Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was £-0.06 Mil. It means Roquefort Therapeutics's Accounts Receivable increased by £0.06 Mil from Dec. 2022 to Dec. 2023 .

Roquefort Therapeutics's Accounts Receivable for the quarter that ended in Jun. 2024 was £0.09 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Roquefort Therapeutics's liquidation value for the six months ended in Jun. 2024 was £-0.48 Mil.

Roquefort Therapeutics Change In Receivables Historical Data

The historical data trend for Roquefort Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Change In Receivables Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Change In Receivables

-0.02

-0.06

Roquefort Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Change In Receivables	Get a 7-Day Free Trial			2.08	-2.10	-0.09	0.03	0.07

Roquefort Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.10 Mil.

Roquefort Therapeutics (LSE:ROQ) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Roquefort Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.087	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Roquefort Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Roquefort Therapeutics's liquidation value for the quarter that ended in Jun. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.596	-	1.145	+	0.75 * 0.087	+	0.5 * 0
=	-0.48

Roquefort Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines

No Headlines